Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 4:38 pm Purchase | 2026-03-31 | 13G | XILIO THERAPEUTICS INC XLO | ORBIMED ADVISORS LLC | 642,000 9.990% | 642,000 (New Position) | Filing History |
| 2026-05-15 4:30 pm Purchase | 2026-03-31 | 13G | XILIO THERAPEUTICS INC XLO | BCLS II Equity Opportunities, LP | 664,021 9.990% | 216,897 (+48.51%) | Filing History |
| 2026-05-15 4:24 pm Sale | 2026-03-31 | 13G | XILIO THERAPEUTICS INC XLO | Point72 Asset Management, L.P. | 0 0.000% | -571,429 (Position Closed) | Filing History |
| 2026-05-15 08:06 am Purchase | 2026-03-31 | 13G | XILIO THERAPEUTICS INC XLO | Sirenia Capital Management LP | 1,142,862 9.900% | 1,142,862 (New Position) | Filing History |
| 2026-02-17 4:30 pm Purchase | 2025-12-31 | 13G | XILIO THERAPEUTICS INC XLO | BCLS II Equity Opportunities, LP | 447,124 8.500% | 120,923 (+37.07%) | Filing History |
| 2026-02-17 10:00 am Purchase | 2025-12-31 | 13G | XILIO THERAPEUTICS INC XLO | STEMPOINT CAPITAL LP | 430,716 8.400% | 145,002 (+50.75%) | Filing History |
| 2026-02-13 5:31 pm Sale | 2025-12-31 | 13G | XILIO THERAPEUTICS INC XLO | Frazier Life Sciences Public Fund, L.P. | 334,034 6.700% | -247,467 (-42.56%) | Filing History |
| 2026-02-12 4:39 pm Purchase | 2025-12-31 | 13G | XILIO THERAPEUTICS INC XLO | GILEAD SCIENCES INC. GILD | 1,036,977 19.900% | 278,838 (+36.78%) | Filing History |
| 2025-12-11 5:55 pm Purchase | 2025-12-04 | 13G | XILIO THERAPEUTICS INC XLO | Coastlands Capital LP | 381,862 9.990% | 381,862 (New Position) | Filing History |
| 2025-11-14 4:02 pm Purchase | 2025-09-30 | 13G | XILIO THERAPEUTICS INC XLO | Point72 Asset Management, L.P. | 571,429 9.900% | 285,715 (+100.00%) | Filing History |
| 2025-11-14 10:00 am Purchase | 2025-09-30 | 13G | XILIO THERAPEUTICS INC XLO | STEMPOINT CAPITAL LP | 285,714 7.200% | 285,714 (New Position) | Filing History |
| 2025-08-14 4:42 pm Purchase | 2025-06-30 | 13G | XILIO THERAPEUTICS INC XLO | GILEAD SCIENCES INC. GILD | 758,139 19.900% | 107,750 (+16.57%) | Filing History |
| 2025-08-14 1:47 pm Purchase | 2025-06-30 | 13G | XILIO THERAPEUTICS INC XLO | Frazier Life Sciences Public Fund, L.P. | 581,501 9.900% | 170,987 (+41.65%) | Filing History |
| 2025-06-17 5:28 pm Purchase | 2025-06-05 | 13G | XILIO THERAPEUTICS INC XLO | Point72 Asset Management, L.P. | 285,714 7.200% | 285,714 (New Position) | Filing History |
| 2025-06-12 4:55 pm Purchase | 2025-06-05 | 13G | XILIO THERAPEUTICS INC XLO | Frazier Life Sciences Public Fund, L.P. | 410,514 9.900% | 410,514 (New Position) | Filing History |
| 2025-05-15 10:48 am Sale | 2025-03-31 | 13G | XILIO THERAPEUTICS INC XLO | Rock Springs Capital Management LP | 0 0.000% | -214,518 (Position Closed) | Filing History |
| 2025-02-18 4:15 pm Purchase | 2025-02-11 | 13G | XILIO THERAPEUTICS INC XLO | AbbVie Inc. ABBV | 310,559 9.000% | 310,559 (New Position) | Filing History |
| 2024-12-19 4:15 pm Purchase | 2024-12-18 | 13G | XILIO THERAPEUTICS INC XLO | GILEAD SCIENCES INC. GILD | 650,389 19.900% | 125,712 (+23.96%) | Filing History |
| 2024-11-14 5:44 pm Purchase | 2024-09-30 | 13G | XILIO THERAPEUTICS INC XLO | BCLS II Equity Opportunities, LP | 326,201 11.000% | 229,867 (+238.61%) | Filing History |
| 2024-11-14 4:30 pm Sale | 2024-09-30 | 13G | XILIO THERAPEUTICS INC XLO | Atlas Venture Fund XI, L.P. | 0 0.000% | -144,529 (Position Closed) | Filing History |